Autopsy report · NCT01856023

HD IL-2 + Ipilimumab in Patients With Metastatic Melanoma

“slow accrual \& early closure”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 2 years 2 months before it stopped.
• 29 participants enrolled.
• Results were posted on the registry 8 years 5 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 4

Sponsor

Clinigen, Inc.

Sponsor type

Industry

Conditions

Metastatic Melanoma

Interventions

High Dose Interleukin-2; Ipilimumab

Participants

29

Sites

12

Countries

United States

Trials that died the same way

• Bevacizumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER-2/NEU
  “Closed early due to slow accrual” (79% match in meaning)
• Lenalidomide Combined With Vorinostat/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Diffuse Large B-Cell Lymphoma of the ABC Subtype
  “Closed due to very slow accrual” (70% match in meaning)
• Use of Rituximab in Opsoclonus-Myoclonus in Children With Neuroblastoma
  “Closed early due to low accrual.” (70% match in meaning)
• T-Cell Depletion, Donor Hematopoietic Stem Cell Transplant (HSCT), and T-Cell Infusions in Treating Patients With Hematologic Cancer or Other Diseases
  “slow accrual” (69% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.